SEQUENOM Announces Promotion of Clarke Neumann To Vice President and General Counsel

Apr 25, 2001, 01:00 ET from SEQUENOM Inc.

    SAN DIEGO, April 25 /PRNewswire Interactive News Release/ -- SEQUENOM(TM),
 Inc. (Nasdaq:   SQNM) announced today the promotion of Clarke Neumann to the
 position of Vice President and General Counsel.  Neumann has played an
 integral role in the development of legal strategies for the Company,
 including broad input in the areas of business development, corporate
 administration and intellectual property.
     Neumann joined SEQUENOM in July of 1999 as Corporate Counsel.  Prior to
 joining SEQUENOM, he practiced at the law firm Lyon & Lyon LLP, specializing
 in intellectual property litigation and business matters.  Neumann earned his
 law degree from Loyola Law School in Los Angeles, holds a Bachelor of Science
 degree in Chemical Engineering from Pennsylvania State University, and is
 registered to practice before the United States Patent and Trademark Office.
 
     About SEQUENOM
     SEQUENOM is leading a worldwide effort to identify genes and genetic
 variations with significant impact on human health.  Using its innovative
 technologies, information and scientific strategy, the Company is rapidly
 translating data generated from the Human Genome Project into medically
 important applications.  Breaking through the limitations of traditional
 research, SEQUENOM's MassARRAY(TM) product line, SNP assay database and
 disease gene discovery program are generating results that position SEQUENOM
 and its customers and collaborators to quickly capture novel leads to utilize
 in new genetics-based diagnostics, drugs and therapies.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the Securities Exchange Act
 of 1934, as amended.  Such forward-looking statements are subject to factors
 that could cause actual results to differ materially for SEQUENOM from those
 projected.  Those factors include risks and uncertainties relating to
 technological approaches, dependence on collaborative partners, the specific
 results generated and successful performance under these and other
 collaborative agreements, product development, manufacturing, market
 acceptance, cost and pricing of SEQUENOM products, competition, the
 intellectual property of others, patent protection and other risk factors
 discussed from time to time in SEQUENOM's reports and filings with the
 Securities and Exchange Commission, including SEQUENOM's Annual Report on Form
 10-K for the year ended December 31, 2001.  SEQUENOM expressly disclaims any
 obligation or undertaking to release publicly any updates or revisions to any
 forward-looking statements contained herein to reflect any change in
 SEQUENOM's expectations with regard thereto or any change in events,
 conditions, or circumstances on which any such statements are based.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X73333272
 
 

SOURCE SEQUENOM Inc.
    SAN DIEGO, April 25 /PRNewswire Interactive News Release/ -- SEQUENOM(TM),
 Inc. (Nasdaq:   SQNM) announced today the promotion of Clarke Neumann to the
 position of Vice President and General Counsel.  Neumann has played an
 integral role in the development of legal strategies for the Company,
 including broad input in the areas of business development, corporate
 administration and intellectual property.
     Neumann joined SEQUENOM in July of 1999 as Corporate Counsel.  Prior to
 joining SEQUENOM, he practiced at the law firm Lyon & Lyon LLP, specializing
 in intellectual property litigation and business matters.  Neumann earned his
 law degree from Loyola Law School in Los Angeles, holds a Bachelor of Science
 degree in Chemical Engineering from Pennsylvania State University, and is
 registered to practice before the United States Patent and Trademark Office.
 
     About SEQUENOM
     SEQUENOM is leading a worldwide effort to identify genes and genetic
 variations with significant impact on human health.  Using its innovative
 technologies, information and scientific strategy, the Company is rapidly
 translating data generated from the Human Genome Project into medically
 important applications.  Breaking through the limitations of traditional
 research, SEQUENOM's MassARRAY(TM) product line, SNP assay database and
 disease gene discovery program are generating results that position SEQUENOM
 and its customers and collaborators to quickly capture novel leads to utilize
 in new genetics-based diagnostics, drugs and therapies.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the Securities Exchange Act
 of 1934, as amended.  Such forward-looking statements are subject to factors
 that could cause actual results to differ materially for SEQUENOM from those
 projected.  Those factors include risks and uncertainties relating to
 technological approaches, dependence on collaborative partners, the specific
 results generated and successful performance under these and other
 collaborative agreements, product development, manufacturing, market
 acceptance, cost and pricing of SEQUENOM products, competition, the
 intellectual property of others, patent protection and other risk factors
 discussed from time to time in SEQUENOM's reports and filings with the
 Securities and Exchange Commission, including SEQUENOM's Annual Report on Form
 10-K for the year ended December 31, 2001.  SEQUENOM expressly disclaims any
 obligation or undertaking to release publicly any updates or revisions to any
 forward-looking statements contained herein to reflect any change in
 SEQUENOM's expectations with regard thereto or any change in events,
 conditions, or circumstances on which any such statements are based.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X73333272
 
 SOURCE  SEQUENOM Inc.